The Cardiovascular Effects of Sunitinib Therapy: Off Target Changes in Cardiac Metabolism and Ventricular Vascular Mechanics (CREST)
Latest Information Update: 31 Mar 2023
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms CREST
- 01 Oct 2018 Status changed from recruiting to completed.
- 11 Apr 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017.
- 15 Jun 2015 Planned End Date changed from 1 Apr 2014 to 1 Apr 2016, according to ClinicalTrials.gov record.